KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Shares Issued: 2018-2025

Historic Shares Issued for Aquestive Therapeutics (AQST) over the last 2 years, with Sep 2025 value amounting to $296,000.

  • Aquestive Therapeutics' Shares Issued rose 53.37% to $296,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 39.82%. This contributed to the annual value of $732,000 for FY2024, which is 1776.92% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Shares Issued stood at $296,000 for Q3 2025, which was up 492.00% from $50,000 recorded in Q2 2025.
  • Aquestive Therapeutics' Shares Issued's 5-year high stood at $9.9 million during Q1 2021, with a 5-year trough of -$24.4 million in Q4 2021.
  • Moreover, its 3-year median value for Shares Issued was $121,500 (2024), whereas its average is $186,167.
  • Over the last 5 years, Aquestive Therapeutics' Shares Issued had its largest YoY gain of 13,793.55% in 2021, and its largest YoY loss of 503.09% in 2021.
  • Over the past 5 years, Aquestive Therapeutics' Shares Issued (Quarterly) stood at -$24.4 million in 2021, then soared by 84.55% to -$3.8 million in 2022, then soared by 100.21% to $8,000 in 2023, then reached $193,000 in 2024, then spiked by 53.37% to $296,000 in 2025.
  • Its Shares Issued was $296,000 in Q3 2025, compared to $50,000 in Q2 2025 and $193,000 in Q3 2024.